Astragaloside IV Alleviates Heart Failure by Promoting Angiogenesis Through the JAK-STAT3 Pathway

Overview

Journal Pharm Biol

Specialties Pharmacology
Pharmacy

Date 2019 Mar 26

PMID 30905241

Citations 23

Authors

Yan-Bo Sui

Yu Wang

Li Liu

Feng Liu

Yi-Qing Zhang

Affiliations

Soon will be listed here.

Abstract

Context: Heart failure (HF) is one of the most serious diseases worldwide. Astragaloside IV (ASI) is widely used for the treatment of cardiovascular disease in China.

Objective: To evaluate the protective effect of ASI on the HF in a Sprague-Dawley rat model of left coronary artery ligation, and investigate the angiogenesis-related mechanisms.

Materials And Methods: Left coronary artery was ligated to induce a rat model of HF, and the rats were treated with vehicle (saline) or different doses of ASI (0.1, 0.3 and 1 mg/kg/day) by oral gavage for 6 weeks. Cardiac function was evaluated by echocardiography. Infarct size was determined by triphenyltetrazolium chloride staining. Cardiac vascular density was analyzed by microangiography. Real-time PCR, Western blot and chromatin immunoprecipitation were performed to investigate the mechanisms.

Results: ASI treatment improved the body weight and survival rate of HF rats, as well as the cardiac function of HF rats, with significantly improved ejection fraction (75.27 ± 5.75% vs. 36.26 ± 4.14%) and fractional shortening (45.39 ± 3.66% vs. 17.88 ± 1.32%). ASI reduced the infarct size of the HF rats by 47%. ASI promoted angiogenesis, with increased vascular density (2.08-fold) and induced mRNA expression of CD31 (1.81-fold) and VEGF (2.70-fold) in the ischemic heart. Furthermore, ASI induced the phosphorylation of JAK (1.89-fold) and STAT3 (2.95-fold), as well as the activity of VEGF promoter which was regulated by STAT3.

Discussion And Conclusions: ASI alleviated HF by promoting angiogenesis through JAK-STAT3 pathway, providing novel alternative strategies to prevent HF in the future.

Citing Articles

Recent advances of traditional Chinese medicine against cardiovascular disease: overview and potential mechanisms.

Dai J, Qiu L, Lu Y, Li M Front Endocrinol (Lausanne). 2024; 15:1366285.

PMID: 39403576 PMC: 11471557. DOI: 10.3389/fendo.2024.1366285.

Astragaloside IV ameliorates pressure overload-induced heart failure by enhancing angiogenesis through HSF1/VEGF pathway.

Du P, Xu L, Wang Y, Jiao T, Cheng J, Zhang C Heliyon. 2024; 10(17):e37019.

PMID: 39296120 PMC: 11408759. DOI: 10.1016/j.heliyon.2024.e37019.

Comparative efficacy of the five most common traditional Chinese medicine monomers in reducing intimal hyperproliferation in arterial balloon injury models: A network meta-analysis.

Xie L, Mao T, Gao Q, Pan Y, Yang Z, Qu X Heliyon. 2024; 10(17):e36327.

PMID: 39263082 PMC: 11387273. DOI: 10.1016/j.heliyon.2024.e36327.

Traditional Chinese Medicine and renal regeneration: experimental evidence and future perspectives.

Zhang D, Jiang H, Yang X, Zheng S, Li Y, Liu S Chin Med. 2024; 19(1):77.

PMID: 38831435 PMC: 11149241. DOI: 10.1186/s13020-024-00935-9.

The Effect of Empagliflozin on Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway in Patients with Type 2 Cardiorenal Syndrome.

Zhou P, Tang X, Deng Y, Wu R, Yi Y, Deng H Anatol J Cardiol. 2024; .

PMID: 38445622 PMC: 11059222. DOI: 10.14744/AnatolJCardiol.2024.2736.

References

Bui A, Horwich T, Fonarow G . Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2010; 8(1):30-41. PMC: 3033496. DOI: 10.1038/nrcardio.2010.165. View

Fan D, Takawale A, Shen M, Wang W, Wang X, Basu R . Cardiomyocyte A Disintegrin And Metalloproteinase 17 (ADAM17) Is Essential in Post-Myocardial Infarction Repair by Regulating Angiogenesis. Circ Heart Fail. 2015; 8(5):970-9. DOI: 10.1161/CIRCHEARTFAILURE.114.002029. View

Zhang L, Liu Q, Lu L, Zhao X, Gao X, Wang Y . Astragaloside IV stimulates angiogenesis and increases hypoxia-inducible factor-1α accumulation via phosphatidylinositol 3-kinase/Akt pathway. J Pharmacol Exp Ther. 2011; 338(2):485-91. DOI: 10.1124/jpet.111.180992. View

Sinclair S . Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. Altern Med Rev. 1998; 3(5):338-44. View

Levy D, Darnell Jr J . Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002; 3(9):651-62. DOI: 10.1038/nrm909. View

Wang S, Xu Y, Chen J, Yang C, Chen X . Astragaloside IV stimulates angiogenesis and increases nitric oxide accumulation via JAK2/STAT3 and ERK1/2 pathway. Molecules. 2013; 18(10):12809-19. PMC: 6270590. DOI: 10.3390/molecules181012809. View

Pfeffer M, Pfeffer J, Steinberg C, Finn P . Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985; 72(2):406-12. DOI: 10.1161/01.cir.72.2.406. View

Carmeliet P . Angiogenesis in life, disease and medicine. Nature. 2005; 438(7070):932-6. DOI: 10.1038/nature04478. View

Zhao Z, Wang W, Wang F, Zhao K, Han Y, Xu W . Effects of Astragaloside IV on heart failure in rats. Chin Med. 2009; 4:6. PMC: 2674594. DOI: 10.1186/1749-8546-4-6. View

10.

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

11.

Wang C, Li Y, Yang X, Bi S, Zhang Y, Han D . Tetramethylpyrazine and Astragaloside IV Synergistically Ameliorate Left Ventricular Remodeling and Preserve Cardiac Function in a Rat Myocardial Infarction Model. J Cardiovasc Pharmacol. 2016; 69(1):34-40. DOI: 10.1097/FJC.0000000000000437. View

12.

van der Laan A, Piek J, van Royen N . Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol. 2009; 6(8):515-23. DOI: 10.1038/nrcardio.2009.103. View

13.

Schumacher B, Pecher P, von Specht B, Stegmann T . Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 1998; 97(7):645-50. DOI: 10.1161/01.cir.97.7.645. View

14.

Losordo D, Vale P, Symes J, Dunnington C, Esakof D, Maysky M . Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation. 1998; 98(25):2800-4. DOI: 10.1161/01.cir.98.25.2800. View

15.

Fletcher P, Pfeffer J, Pfeffer M, Braunwald E . Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ Res. 1981; 49(3):618-26. DOI: 10.1161/01.res.49.3.618. View

16.

Omura T, Yoshiyama M, Ishikura F, Kobayashi H, Takeuchi K, Beppu S . Myocardial ischemia activates the JAK-STAT pathway through angiotensin II signaling in in vivo myocardium of rats. J Mol Cell Cardiol. 2001; 33(2):307-16. DOI: 10.1006/jmcc.2000.1303. View

17.

Olsson A, Dimberg A, Kreuger J, Claesson-Welsh L . VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006; 7(5):359-71. DOI: 10.1038/nrm1911. View

18.

Dong Z, Zhao P, Xu M, Zhang C, Guo W, Chen H . Astragaloside IV alleviates heart failure via activating PPARα to switch glycolysis to fatty acid β-oxidation. Sci Rep. 2017; 7(1):2691. PMC: 5457407. DOI: 10.1038/s41598-017-02360-5. View

19.

Yla-Herttuala S, Alitalo K . Gene transfer as a tool to induce therapeutic vascular growth. Nat Med. 2003; 9(6):694-701. DOI: 10.1038/nm0603-694. View

20.

Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B . Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res. 2004; 95(2):187-95. DOI: 10.1161/01.RES.0000134921.50377.61. View